Experienced in Dendritic Cell Tumor

Dr. Abhimanyu Ghose

Hematology | Oncology
Honorhealth Ambulatory
10510 N 92nd St, 
Scottsdale, AZ 
Accepting New Patients
Offers Telehealth
Experienced in Dendritic Cell Tumor
Honorhealth Ambulatory
10510 N 92nd St, 
Scottsdale, AZ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Abhimanyu Ghose is a Hematologist and an Oncologist in Scottsdale, Arizona. Dr. Ghose is rated as an Experienced provider by MediFind in the treatment of Dendritic Cell Tumor. His top areas of expertise are Adult Soft Tissue Sarcoma, Bone Tumor, Familial Prostate Cancer, and Familial Colorectal Cancer. Dr. Ghose is currently accepting new patients.

His clinical research consists of co-authoring 16 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in OH
Hospital Affiliations
Mercy Gilbert Medical Center
Honor Health John C. Lincoln Medical Center
Chandler Regional Medical Center
Languages Spoken
English
Bengali
Hindi
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
EMI Health
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MercyCare
  • EPO
  • HMO
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VibrantRx
  • MEDICARE PDP
  • OTHER MEDICARE
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

HONORHEALTH AMBULATORY
10510 N 92nd St, Scottsdale, AZ 85258
Other Locations
HONORHEALTH AMBULATORY
7695 S Research Dr, Tempe, AZ 85284

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With NSCLC as First Line Therapy or When Progressing on Single-Agent First-Line Anti PD (L)1 Therapy
A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With NSCLC as First Line Therapy or When Progressing on Single-Agent First-Line Anti PD (L)1 Therapy
Enrollment Status: Active_not_recruiting
Publish Date: April 30, 2024
Intervention Type: Biological, Drug
Study Drugs: Tomivosertib, Pembrolizumab
Study Phase: Phase 2
An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
Enrollment Status: Completed
Publish Date: June 16, 2022
Intervention Type: Drug
Study Drugs: Itacitinib, Ruxolitinib
Study Phase: Phase 2
A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)
A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)
Enrollment Status: Terminated
Publish Date: January 20, 2021
Intervention Type: Drug, Biological
Study Phase: Phase 2
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
Enrollment Status: Terminated
Publish Date: September 11, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2
View 3 Less Clinical Trials

13 Total Publications

Advanced biliary tract cancer: clinical outcomes with ABC-02 regimen and analysis of prognostic factors in a tertiary care center in the United States.
Advanced biliary tract cancer: clinical outcomes with ABC-02 regimen and analysis of prognostic factors in a tertiary care center in the United States.
Journal: Journal of gastrointestinal oncology
Published: January 13, 2017
Similar Doctors
Experienced in Dendritic Cell Tumor
Dr. Fade Mahmoud
Hematology | Oncology
Experienced in Dendritic Cell Tumor
Dr. Fade Mahmoud
Hematology | Oncology

Banner Cancer Center Specialists LLC

2946 E Banner Gateway Dr, 
Gilbert, AZ 
 (16.3 miles away)
480-256-6444
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Fade Mahmoud is a Hematologist and an Oncologist in Gilbert, Arizona. Dr. Mahmoud is rated as a Distinguished provider by MediFind in the treatment of Dendritic Cell Tumor. His top areas of expertise are Melanoma, Bone Tumor, Adult Soft Tissue Sarcoma, Alveolar Soft Part Sarcoma, and Orchiectomy.

Experienced in Dendritic Cell Tumor
Dr. Sujith R. Kalmadi
Hematology Oncology | Hematology | Oncology
Experienced in Dendritic Cell Tumor
Dr. Sujith R. Kalmadi
Hematology Oncology | Hematology | Oncology

Ironwood Physicians PC

685 S Dobson Rd, 
Chandler, AZ 
 (19.8 miles away)
480-821-2838
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sujith Kalmadi is a Hematologist Oncology specialist and a Hematologist in Chandler, Arizona. Dr. Kalmadi is rated as a Distinguished provider by MediFind in the treatment of Dendritic Cell Tumor. His top areas of expertise are Lung Cancer, Familial Colorectal Cancer, Colorectal Cancer, and Severe Congenital Neutropenia. Dr. Kalmadi is currently accepting new patients.

Experienced in Dendritic Cell Tumor
Dr. Anita M. Koszyk-Szewczyk
Hematology Oncology | Hematology | Oncology
Experienced in Dendritic Cell Tumor
Dr. Anita M. Koszyk-Szewczyk
Hematology Oncology | Hematology | Oncology

Ironwood Physicians PC

695 S Dobson Rd, 
Chandler, AZ 
 (19.8 miles away)
480-821-2838
Languages Spoken:
English, Polish
See accepted insurances
Accepting New Patients
Offers Telehealth

Anita Koszyk-Szewczyk is a Hematologist Oncology specialist and a Hematologist in Chandler, Arizona. Dr. Koszyk-Szewczyk is rated as a Distinguished provider by MediFind in the treatment of Dendritic Cell Tumor. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, and Bone Marrow Aspiration. Dr. Koszyk-Szewczyk is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ghose's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 127 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile